(Q35552416)

English

Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers

scientific article published on 11 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Funda Meric-Bernstam

5

object named as

Funda Meric-Bernstam

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Ana Maria Gonzalez-Angulo

10

object named as

Ana M Gonzalez-Angulo

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Gabriel N Hortobagyi

9

object named as

Gabriel N Hortobagyi

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

author name string

Kanwal P S Raghav

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Leonel F Hernandez-Aya

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Xiudong Lei

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Marianan Chavez-Macgregor

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Thomas A Buchholz

6

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Aysegul Sahin

7

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Kim-Anh Do

8

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

language of work or name

0 references

publication date

11 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

118

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

1498-1506

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Assessment of Tissue Estrogen and Progesterone Receptor Levels: A Survey of Current Practice, Techniques, and Quantitation Methods

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

12 July 2018

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26431

21 January 2018

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26431

21 January 2018

Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26431

21 January 2018

Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26431

21 January 2018

HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217101

26 September 2018

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26431

21 January 2018

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The world Health Organization Histological Typing of Breast Tumors--Second Edition. The World Organization

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nuclear structure in cancer tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of primary breast cancer with chemotherapy and tamoxifen

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/21837669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.26431

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35552416&oldid=1606500249"